These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 24706704)

  • 1. Thrombotic microangiopathy (TMA) in a patient treated with antiviral therapy for hepatitis C.
    Evans R; Pavan M; Suri D; Harber M
    BMJ Case Rep; 2014 Apr; 2014():. PubMed ID: 24706704
    [No Abstract]   [Full Text] [Related]  

  • 2. Thrombotic microangiopathy complicating pegylated interferon treatment of hepatitis C infection.
    Iskander D; Wickremasinghe M; Bain BJ
    Am J Hematol; 2011 Oct; 86(10):859. PubMed ID: 21630311
    [No Abstract]   [Full Text] [Related]  

  • 3. Effects of Smoking on Pegylated Interferon alpha 2a and First Generation Protease Inhibitor-based Antiviral Therapy in Naïve Patients Infected with Hepatitis C Virus Genotype 1.
    Zimmermann T; Hueppe D; Mauss S; Buggisch P; Pfeiffer-Vornkahl H; Grimm D; Galle PR; Alshuth U
    J Gastrointestin Liver Dis; 2016 Mar; 25(1):15-24. PubMed ID: 27014750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Avoiding therapeutic pitfalls: the rational use of specifically targeted agents against hepatitis C infection.
    McGovern BH; Abu Dayyeh BK; Chung RT
    Hepatology; 2008 Nov; 48(5):1700-12. PubMed ID: 18972443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A patient with acute hepatitis C and possible IFN toxicity.
    Licata A; Di Marco V; Craxì A
    Dig Liver Dis; 2003 May; 35(5):372-3. PubMed ID: 12846412
    [No Abstract]   [Full Text] [Related]  

  • 6. Sarcoidosis developing after treatment with interferon alpha in a patient with hepatitis C: An association every physician should know.
    Flores-Robles BJ; Sangüesa-Gómez CP; Barbadillo Mateos C; Roustán-Gullón LG; Kovtun I
    Rev Gastroenterol Mex; 2017; 82(2):185-186. PubMed ID: 27161792
    [No Abstract]   [Full Text] [Related]  

  • 7. [Ischemic anterior optic neuropathy complicating interferon alpha-2a and ribavirin treatment for acute hepatitis C].
    Yaghi C; Baz P; Koussa S; Daniel F; Haddad F; Sayegh R
    Gastroenterol Clin Biol; 2005 May; 29(5):616-7. PubMed ID: 15980766
    [No Abstract]   [Full Text] [Related]  

  • 8. Rapid onset of hematotoxic effects after interferon alpha in hepatitis C.
    Dormann H; Krebs S; Muth-Selbach U; Brune K; Schuppan D; Hahn EG; Schneider HT
    J Hepatol; 2000 Jun; 32(6):1041-2. PubMed ID: 10898329
    [No Abstract]   [Full Text] [Related]  

  • 9. Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial.
    Forns X; Lawitz E; Zeuzem S; Gane E; Bronowicki JP; Andreone P; Horban A; Brown A; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; Scott J; De La Rosa G; Kalmeijer R; Sinha R; Beumont-Mauviel M
    Gastroenterology; 2014 Jun; 146(7):1669-79.e3. PubMed ID: 24602923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Case of mania induced by withdrawal of interferon-alpha in a patient affected by bipolar disorder.
    Rossi A; Renzetti D; D'Albenzio L; Gianfelice D; Kalyvoka A; Rinaldi O
    Psychiatry Clin Neurosci; 2002 Dec; 56(6):647-8. PubMed ID: 12485309
    [No Abstract]   [Full Text] [Related]  

  • 11. [Myasthenia during interferon alpha therapy].
    Quilichini R; Mazzerbo F; Baume D; Amiel O; Lafeuillade A; Pellegrino P
    Presse Med; 1995 Sep 2-9; 24(25):1178. PubMed ID: 7567837
    [No Abstract]   [Full Text] [Related]  

  • 12. Side effects. Bone problems may occur with hepatitis treatment.
    TreatmentUpdate; 2000 Sep; 12(6):7-8. PubMed ID: 12132465
    [No Abstract]   [Full Text] [Related]  

  • 13. A promising new anti-HCV protease inhibitor.
    Sulkowski M
    Hopkins HIV Rep; 2003 Jan; 15(1):7. PubMed ID: 12542005
    [No Abstract]   [Full Text] [Related]  

  • 14. Peripheral nervous system involvement in a haemodialysis patient treated with pegylated interferon.
    Ruiz-Fuentes MC; Rubert-Gómez De Quero A; De Gracia-Guindo C; Galindo-Sacristán P; Osuna-Ortega A
    Nefrologia; 2012; 32(6):863-5. PubMed ID: 23169385
    [No Abstract]   [Full Text] [Related]  

  • 15. [Sarcoidosis associated with the treatment of hepatitis C: case report and Spanish literature review].
    Trullàs JC; Hernández-Marcet P; Bisbe J
    Med Clin (Barc); 2011 May; 136(14):649-50. PubMed ID: 21051060
    [No Abstract]   [Full Text] [Related]  

  • 16. Interferon-induced obsessive-compulsive disorder.
    DeRosse P; Szeszko PR; Malhotra AK
    Gen Hosp Psychiatry; 2006; 28(4):357-8. PubMed ID: 16814637
    [No Abstract]   [Full Text] [Related]  

  • 17. Catatonia associated with pegylated interferon-α 2b and ribavirin for hepatitis C.
    Quinn D; Kuchler E; Deming P; Arora S
    Psychosomatics; 2012; 53(4):400-1. PubMed ID: 22748752
    [No Abstract]   [Full Text] [Related]  

  • 18. [Therapy of chronic hepatitis C].
    Schaffstein S; Rampini SK; Müllhaupt B
    Praxis (Bern 1994); 2014 Apr; 103(8):423-36. PubMed ID: 24713377
    [No Abstract]   [Full Text] [Related]  

  • 19. Severe interstitial pneumonitis secondary to pegylated interferon alpha-2b and ribavirin treatment of hepatitis C infection.
    Fuhrmann V; Kramer L; Bauer E; Laferl H; Tucek G; Dekan G; Schenk P
    Dig Dis Sci; 2004; 49(11-12):1966-70. PubMed ID: 15628735
    [No Abstract]   [Full Text] [Related]  

  • 20. Hepatitis C in 2012: On the fast track towards IFN-free therapy for hepatitis C?
    Wedemeyer H
    Nat Rev Gastroenterol Hepatol; 2013 Feb; 10(2):76-8. PubMed ID: 23296251
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.